Earnings summaries and quarterly performance for Senseonics Holdings.
Executive leadership at Senseonics Holdings.
Timothy Goodnow
Detailed
President and Chief Executive Officer
CEO
FK
Francine Kaufman
Detailed
Chief Medical Officer
FS
Frederick Sullivan
Detailed
Chief Financial Officer, Secretary and Treasurer
KH
Kenneth Horton
Detailed
General Counsel and Corporate Development Advisor
MJ
Mukul Jain
Detailed
Chief Operating Officer
Board of directors at Senseonics Holdings.
Research analysts who have asked questions during Senseonics Holdings earnings calls.
Marie Thibault
BTIG
4 questions for SENS
Also covers: ABT, ARAY, ATRC +15 more
AP
Anthony Petrone
Mizuho Group
3 questions for SENS
Also covers: ADMA, ALC, AXGN +24 more
BH
Ben Haynor
Lake Street Capital Markets
2 questions for SENS
Also covers: APYX, ATEC, BFLY +12 more
Jonathan Block
Stifel Financial Corp.
2 questions for SENS
Also covers: ALGN, COO, CUTR +12 more
JJ
Joshua Jennings
TD Cowen
2 questions for SENS
Also covers: ABT, ALUR, ATEC +22 more
Matt Miksic
Barclays Investment Bank
2 questions for SENS
Also covers: ABT, ALC, ATEC +17 more
Sean Lee
H.C. Wainwright & Co.
2 questions for SENS
Also covers: ATEC, CASI, CTSO +4 more
MB
Mathew Blackman
Stifel
1 question for SENS
Also covers: AHCO, ATEC, BBNX +10 more
MT
Matthew Taylor
Jefferies
1 question for SENS
Also covers: ALUR, BDX, BSX +21 more
Sam Eiber
BTIG, LLC
1 question for SENS
Also covers: AIRS, APYX, EMBC +8 more
VB
Vernon Bernardino
H.C. Wainwright & Co.
1 question for SENS
Also covers: CANF, ELDN, GALT +6 more
Recent press releases and 8-K filings for SENS.
Senseonics Holdings, Inc. Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Outlook
SENS
Earnings
Guidance Update
Product Launch
- Senseonics Holdings, Inc. reported Q4 2025 revenue of $14.3 million, an increase of 72% year-over-year, and full-year 2025 revenue of $35.3 million, up 57% year-over-year. The net loss for Q4 2025 was $20.8 million (or $0.46 loss per share) and for full-year 2025 was $69.1 million (or $1.66 loss per share).
- Key accomplishments in 2025 included 103% new patient growth in the U.S., receiving CE Mark approval for Eversense 365 in Europe, and launching the Eversense 365 AID system integration with twiist in the U.S..
- The company also executed agreements to take back commercialization and distribution of Eversense starting January 1, 2026, and received IDE approval from the FDA for the Gemini sensor pivotal trial, with completion expected in the second half of 2026.
- For full-year 2026, Senseonics expects global net revenue to be approximately $58-$62 million, representing 65% to 76% year-over-year growth, with gross margins of approximately 50%.
4 days ago
Senseonics Holdings Reports Q4 and Full-Year 2025 Results, Provides 2026 Revenue Guidance
SENS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Senseonics Holdings reported Q4 2025 net revenue of $14.3 million, a 72% increase year-over-year, and full-year 2025 revenue of $35.3 million, growing approximately 60% from 2024, with gross margins improving to greater than 50% by year-end.
- The company completed the transition of all commercial activities from Ascensia Diabetes Care back in-house in 2025, eliminating revenue sharing and enhancing its financial profile, with the European transition expected to conclude in the second quarter of 2026.
- Senseonics provided full-year 2026 global net revenue guidance of $58 million-$62 million, projecting 65%-76% year-over-year growth, driven by the commercial transition, European market expansion, and a goal to double its U.S. patient base again.
4 days ago
Senseonics Holdings Reports Strong Q4 and Full Year 2025 Results, Provides 2026 Guidance, and Completes Commercial Transition
SENS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Senseonics reported full year 2025 revenue of $35.3 million, an increase of 60% year-over-year, and Q4 2025 net revenue of $14.3 million, up 72% from the prior year period.
- The company achieved gross margins greater than 50% by the end of 2025 and expects to maintain this for full year 2026.
- A key strategic decision in 2025 was the transition of all commercial activities from Ascensia Diabetes Care back to Senseonics, aiming to eliminate revenue sharing and enhance control over sales and marketing.
- Senseonics provided full year 2026 global net revenue guidance of $58 million-$62 million, representing 65%-76% year-over-year growth, and expects operating expenses between $150 million and $160 million due to commercial integration.
- The company ended 2025 with $94.3 million in cash, restricted cash, and cash equivalents.
4 days ago
Senseonics Holdings Reports Strong 2025 Revenue Growth and Provides 2026 Guidance
SENS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Senseonics reported full year 2025 revenue of $35.3 million, an increase of approximately 60% year-over-year, and Q4 2025 revenue of $14.3 million, up 72% from the prior year period. The company also achieved significant margin improvements, with gross margins reaching greater than 50% by year-end 2025.
- The company successfully transitioned all commercial activities for Eversense 365 from Ascensia Diabetes Care back in-house during 2025, aiming to eliminate revenue sharing and gain greater control over sales and marketing. The European transition is anticipated to conclude in Q2 2026.
- Senseonics achieved a doubling of patients on Eversense in the U.S. in 2025, with new patient starts growing 103%, and aims to double its patient base again in 2026.
- For full year 2026, the company expects global net revenue to be approximately $58 million-$62 million, representing 65%-76% year-over-year growth.
- As of December 31, 2025, cash, restricted cash, and cash equivalents totaled $94.3 million.
4 days ago
Senseonics Holdings Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Outlook
SENS
Earnings
Guidance Update
Product Launch
- Senseonics Holdings generated $14.3 million in revenue for Q4 2025, an increase of 72% year-over-year, and $35.3 million for full year 2025, an increase of 57% year-over-year.
- The company reported a net loss of $20.8 million, or $0.46 loss per share, for Q4 2025, and a net loss of $69.1 million, or $1.66 loss per share, for full year 2025.
- Key accomplishments include receiving CE Mark approval for Eversense 365 in Europe, launching the first Eversense 365 AID system integration with twiist in the U.S., and securing Investigational Device Exemption (IDE) approval from the FDA for the Gemini sensor pivotal trial.
- For full year 2026, Senseonics expects global net revenue to be approximately $58-$62 million, representing 65% to 76% year-over-year growth, with gross margins expected to be approximately 50%.
4 days ago
Senseonics and Sequel Med Tech Announce Full U.S. Availability of twiist™ AID System Integrated with Eversense® 365 CGM
SENS
Product Launch
New Projects/Investments
- On February 19, 2026, Senseonics Holdings, Inc. and Sequel Med Tech, LLC announced the full U.S. availability of the twiist™ Automated Insulin Delivery (AID) System integrated with the Eversense® 365 Continuous Glucose Monitoring (CGM) system.
- This combination is presented as a transformative solution for long-term diabetes management, aiming to significantly reduce the burden of frequent sensor changes and re-pairing while maintaining exceptional CGM accuracy.
- The Eversense 365 is highlighted as the world's only one-year CGM, providing 365 days of uninterrupted, reliable glucose readings and being the most accurate CGM in low glucose ranges.
Feb 19, 2026, 1:00 PM
Senseonics Receives European Approval for Eversense 365 CGM System
SENS
Product Launch
New Projects/Investments
- Senseonics Holdings, Inc. has received CE Mark approval for its Eversense® 365 Continuous Glucose Monitoring (CGM) system, enabling its commercialization in the European Union (EU).
- The Eversense 365 is the world's first and only one-year CGM, which was previously approved by the US FDA in September 2024 and launched in the US in October 2024.
- The company expects to launch Eversense 365 in Germany, Italy, Spain, and Sweden in the coming months, anticipating this expansion to contribute to top-line revenue growth and increase its total addressable market by over 30 million patients in the EU.
- Senseonics is taking full ownership of all commercial activities for Eversense 365 and projects further commercial progress in the U.S. and Europe in 2026, alongside the integration with Sequel’s twiist™ Automated Insulin Delivery (AID) System and the planned completion of the Gemini trial.
Jan 29, 2026, 9:01 PM
Veramatic Appoints New CEO
SENS
CEO Change
Management Change
Hiring
- Veramatic (formerly Accumatic), an accounting control software company for dealerships, announced the appointment of George Sens as Chief Executive Officer, effective December 1, 2025.
- Sens succeeds co-founder Tobey Bryant, who transitioned to Chair of the Board of Directors.
- Sens brings deep auto-tech experience and a track record of scaling SaaS businesses to Veramatic.
- Under Sens' leadership, Veramatic plans to accelerate penetration in franchise dealership groups and expand into new verticals like heavy trucking and RV within the next 12-24 months.
Jan 28, 2026, 12:00 PM
Senseonics Announces Preliminary Unaudited Q4 and Full Year 2025 Revenue and Provides 2026 Guidance
SENS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Senseonics reported preliminary unaudited revenue of approximately $14.2 million for Q4 2025, a 71% increase year-over-year, and approximately $35.2 million for full year 2025, a 57% increase year-over-year.
- The company issued 2026 revenue guidance of $58-$62 million, representing a 65% to 76% increase over 2025 revenue, with an anticipated full-year gross margin of approximately 50%.
- New patient growth in the U.S. increased by 103% in Q4 2025 compared to the same period in 2024, and Senseonics will assume commercialization and distribution of Eversense® from Ascensia Diabetes Care starting January 1, 2026.
- The unaudited balance of cash, cash equivalents, and restricted cash as of December 31, 2025, is expected to be approximately $94.3 million.
Jan 12, 2026, 1:25 PM
Senseonics Announces Commercial Launch of Integrated Eversense 365 and twiist AID System
SENS
Product Launch
New Projects/Investments
- Senseonics Holdings, Inc. and Sequel MedTech, LLC have launched the integration of their products, with the first patients having received a Sequel twiist AID system paired with the Eversense 365 Continuous Glucose Monitor (CGM).
- This integration represents the first time the world's only One Year CGM system (Eversense 365) has been integrated with an Automated Insulin Delivery (AID) system, offering enhanced flexibility and personalization for people with type 1 diabetes.
- The Eversense 365 is highlighted as the only implantable CGM available, providing one year of accurate monitoring with minimal interruptions.
- Broad availability of twiist with Eversense 365 is expected by March 2026.
Jan 8, 2026, 9:01 PM
Quarterly earnings call transcripts for Senseonics Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more